Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIa Study, Evaluating the Safety and Tolerability of Targeted Intraprostatic Administration of PRX302 With Histologically Proven,Clinically Significant Localised, Low to Intermediate Risk Prostate Cancer Associated With MRI Lesion

Next Previous
Trial Profile

Phase IIa Study, Evaluating the Safety and Tolerability of Targeted Intraprostatic Administration of PRX302 With Histologically Proven,Clinically Significant Localised, Low to Intermediate Risk Prostate Cancer Associated With MRI Lesion

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Topsalysin (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Proof of concept
  • Acronyms IDEAL
  • Sponsors Sophiris Bio

    • Most Recent Events

    • 16 May 2017 Results presented at the 112th Annual Meeting of the American Urological Association.
    • 15 May 2017 According to a Sophiris Bio media release, successful data from this proof-of-concept study of topsalysin, will be presented today as a poster at the 112th American Urological Association (AUA) Meeting (2017).
    • 23 Mar 2017 According to a Sophiris Bio media release, data from this trial will be presented at the 32nd Annual European Association of Urology 2017.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top